
Robert A Anders

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11544153/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Gastric Mucosal Devitalization (GMD): Using the Porcine Model to Develop a Novel Endoscopic Bariatric Approach. Obesity Surgery, 2022, 32, 381-390.	2.1	2
2	Identifying the Ideal Target Vessel Size for Bariatric Embolization: Histologic Analysis of Swine and Human Gastric Fundi. Journal of Vascular and Interventional Radiology, 2022, 33, 28-32.	0.5	2
3	Neoadjuvant and adjuvant antitumor vaccination alone or combination with PD1 blockade and CD137 agonism in patients with resectable pancreatic adenocarcinoma Journal of Clinical Oncology, 2022, 40, 558-558.	1.6	7
4	Expanding the immunotherapy roadmap for hepatocellular carcinoma. Cancer Cell, 2022, 40, 252-254.	16.8	9
5	Immune cell atlas of cholangiocarcinomas reveals distinct tumor microenvironments and associated prognoses. Journal of Hematology and Oncology, 2022, 15, 37.	17.0	23
6	Human Colon Cancer–Derived <i>Clostridioides difficile</i> Strains Drive Colonic Tumorigenesis in Mice. Cancer Discovery, 2022, 12, 1873-1885.	9.4	38
7	A feasibility study of combined epigenetic and vaccine therapy in advanced colorectal cancer with pharmacodynamic endpoint. Clinical Epigenetics, 2021, 13, 25.	4.1	11
8	Bacterial-Driven Inflammation and Mutant <i>BRAF</i> Expression Combine to Promote Murine Colon Tumorigenesis That Is Sensitive to Immune Checkpoint Therapy. Cancer Discovery, 2021, 11, 1792-1807.	9.4	43
9	Nuclear PTEN and p53 suppress stress-induced liver cancer through distinct mechanisms. Biochemical and Biophysical Research Communications, 2021, 549, 83-90.	2.1	10
10	Prognostic Implications of the Immune Tumor Microenvironment in Patients With Pancreatic and Gastrointestinal Neuroendocrine Tumors. Pancreas, 2021, 50, 719-726.	1.1	5
11	G-protein coupled receptor 35 (GPR35) regulates the colonic epithelial cell response to enterotoxigenic Bacteroides fragilis. Communications Biology, 2021, 4, 585.	4.4	20
12	A Novel NIPBL-NACC1 Gene Fusion Is Characteristic of the Cholangioblastic Variant of Intrahepatic Cholangiocarcinoma. American Journal of Surgical Pathology, 2021, 45, 1550-1560.	3.7	23
13	Phase I Study of Entinostat and Nivolumab with or without Ipilimumab in Advanced Solid Tumors (ETCTN-9844). Clinical Cancer Research, 2021, 27, 5828-5837.	7.0	18
14	Analysis of multispectral imaging with the AstroPath platform informs efficacy of PD-1 blockade. Science, 2021, 372, .	12.6	114
15	Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunity. Nature Cancer, 2021, 2, 891-903.	13.2	147
16	Spatial UMAP and Image Cytometry for Topographic Immuno-oncology Biomarker Discovery. Cancer Immunology Research, 2021, 9, 1262-1269.	3.4	8
17	Evaluation of Early vs Standard Liver Transplant for Alcohol-Associated Liver Disease. JAMA Surgery, 2021, 156, 1026.	4.3	43
18	PD-L1 (Programmed Death Ligand 1) as a Marker of Acute Cellular Rejection After Heart Transplantation. Circulation: Heart Failure. 2021. 14. e008563.	3.9	6

#	Article	IF	CITATIONS
19	Endothelial Stromal PD-L1 (Programmed Death Ligand 1) Modulates CD8 ⁺ T-Cell Infiltration After Heart Transplantation. Circulation: Heart Failure, 2021, 14, e007982.	3.9	17
20	Vaccine-Induced Intratumoral Lymphoid Aggregates Correlate with Survival Following Treatment with a Neoadjuvant and Adjuvant Vaccine in Patients with Resectable Pancreatic Adenocarcinoma. Clinical Cancer Research, 2021, 27, 1278-1286.	7.0	35
21	Multicenter randomized phase II trial of atezolizumab with or without cobimetinib in biliary tract cancers. Journal of Clinical Investigation, 2021, 131, .	8.2	56
22	Pan-Tumor Pathologic Scoring of Response to PD-(L)1 Blockade. Clinical Cancer Research, 2020, 26, 545-551.	7.0	100
23	A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer. Cancer Medicine, 2020, 9, 1485-1494.	2.8	48
24	The Loss of Nuclear PTEN Increases Tumorigenesis in a Preclinical Mouse Model for Hepatocellular Carcinoma. IScience, 2020, 23, 101548.	4.1	15
25	Bariatric Arterial Embolization with Calibrated Radiopaque Microspheres and an Antireflux Catheter Suppresses Weight Gain and Appetite-Stimulating Hormones in Swine. Journal of Vascular and Interventional Radiology, 2020, 31, 1483-1491.	0.5	12
26	The Immunosuppressive Niche of Soft-Tissue Sarcomas is Sustained by Tumor-Associated Macrophages and Characterized by Intratumoral Tertiary Lymphoid Structures. Clinical Cancer Research, 2020, 26, 4018-4030.	7.0	44
27	Role of baseline volumetric functional MRI in predicting histopathologic grade and patients' survival in hepatocellular carcinoma. European Radiology, 2020, 30, 3748-3758.	4.5	18
28	A Phase II Study of Allogeneic GM-CSF–Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatment for Metastatic Pancreatic Cancer. Clinical Cancer Research, 2020, 26, 5129-5139.	7.0	67
29	Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-Mesothelin (CRS-207) with or without Nivolumab in Patients with Pancreatic Cancer. Clinical Cancer Research, 2020, 26, 3578-3588.	7.0	76
30	Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade. JAMA Oncology, 2019, 5, 1195.	7.1	431
31	Axon Guidance Molecules Promote Perineural Invasion and Metastasis of Orthotopic Pancreatic Tumors in Mice. Gastroenterology, 2019, 157, 838-850.e6.	1.3	88
32	Immunopathologic Stratification of Colorectal Cancer for Checkpoint Blockade Immunotherapy. Cancer Immunology Research, 2019, 7, 1574-1579.	3.4	33
33	Targeting Mechanoresponsive Proteins in Pancreatic Cancer: 4-Hydroxyacetophenone Blocks Dissemination and Invasion by Activating MYH14. Cancer Research, 2019, 79, 4665-4678.	0.9	44
34	Intratumoral Adaptive Immunosuppression and Type 17 Immunity in Mismatch Repair Proficient Colorectal Tumors. Clinical Cancer Research, 2019, 25, 5250-5259.	7.0	46
35	Multiple Immune-Suppressive Mechanisms in Fibrolamellar Carcinoma. Cancer Immunology Research, 2019, 7, 805-812.	3.4	22

Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1., 2019, 7, 40.

#	Article	IF	CITATIONS
37	Noninvasive Detection of Microsatellite Instability and High Tumor Mutation Burden in Cancer Patients Treated with PD-1 Blockade. Clinical Cancer Research, 2019, 25, 7024-7034.	7.0	104
38	Abundant Expression of Lysyl Oxidaseâ€like 2 Protein in Intrahepatic Bile Ducts of Infants With Biliary Atresia. Journal of Pediatric Gastroenterology and Nutrition, 2019, 69, 344-350.	1.8	1
39	Evaluation of Peritumoral Fibrosis in Metastatic Colorectal Adenocarcinoma to the Liver Using Digital Image Analysis. American Journal of Clinical Pathology, 2019, 151, 226-230.	0.7	Ο
40	Human colon mucosal biofilms from healthy or colon cancer hosts are carcinogenic. Journal of Clinical Investigation, 2019, 129, 1699-1712.	8.2	145
41	Chemoradiation-induced alteration of programmed death-ligand 1 and CD8+ tumor-infiltrating lymphocytes in rectal cancer Journal of Clinical Oncology, 2019, 37, 570-570.	1.6	Ο
42	The impact of the immune microenvironment in patients with GEP-NETs Journal of Clinical Oncology, 2019, 37, 267-267.	1.6	0
43	Impact of histological subtype on the prognosis of patients undergoing surgery for colon cancer. Journal of Surgical Oncology, 2018, 117, 1355-1363.	1.7	26
44	Liver Transplantation for Severe Alcoholic Hepatitis, Updated Lessons from the World's Largest Series. Journal of the American College of Surgeons, 2018, 226, 549-557.	0.5	90
45	Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria. Science, 2018, 359, 592-597.	12.6	733
46	Distinction of intrahepatic metastasis from multicentric carcinogenesis in multifocal hepatocellular carcinoma using molecular alterations. Human Pathology, 2018, 72, 127-134.	2.0	21
47	Implications of the tumor immune microenvironment for staging and therapeutics. Modern Pathology, 2018, 31, 214-234.	5.5	278
48	Combining intratumoral Treg depletion with androgen deprivation therapy (ADT): preclinical activity in the Myc-CaP model. Prostate Cancer and Prostatic Diseases, 2018, 21, 113-125.	3.9	46
49	Immune checkpoint inhibitor colitis: the flip side of the wonder drugs. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 472, 125-133.	2.8	59
50	Clinicopathological Distinction of Low-AFP-Secreting vs. High-AFP-Secreting Hepatocellular Carcinomas. Annals of Hepatology, 2018, 17, 1052-1066.	1.5	14
51	Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab. , 2018, 6, 99.		129
52	PD-L1 on host cells is essential for PD-L1 blockade–mediated tumor regression. Journal of Clinical Investigation, 2018, 128, 580-588.	8.2	388
53	Stem Cell Mobilization Is Lifesaving in a Large Animal Preclinical Model of Acute Liver Failure. Annals of Surgery, 2018, 268, 620-631.	4.2	7
54	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC). , 2018, 6, 75.		188

#	Article	IF	CITATIONS
55	Bariatric Arterial Embolization: Effect of Microsphere Size on the Suppression of Fundal Ghrelin Expression and Weight Change in a Swine Model. Radiology, 2018, 289, 83-89.	7.3	18
56	Elective Nodal Irradiation Attenuates the Combinatorial Efficacy of Stereotactic Radiation Therapy and Immunotherapy. Clinical Cancer Research, 2018, 24, 5058-5071.	7.0	213
57	Quantitative Characterization of CD8+ T Cell Clustering and Spatial Heterogeneity in Solid Tumors. Frontiers in Oncology, 2018, 8, 649.	2.8	30
58	Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma. Gut, 2017, 66, 794-801.	12.1	377
59	PBRM1 loss is a late event during the development of cholangiocarcinoma. Histopathology, 2017, 71, 375-382.	2.9	18
60	PD-L1 Expression in Melanoma: A Quantitative Immunohistochemical Antibody Comparison. Clinical Cancer Research, 2017, 23, 4938-4944.	7.0	120
61	Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science, 2017, 357, 409-413.	12.6	4,945
62	Stereotactic Radiotherapy Increases Functionally Suppressive Regulatory T Cells in the Tumor Microenvironment. Cancer Immunology Research, 2017, 5, 992-1004.	3.4	149
63	Derivation of a disease-specific human induced pluripotent stem cell line from a biliary atresia patient. Stem Cell Research, 2017, 24, 25-28.	0.7	4
64	Characterization of the Immune Microenvironment in Hepatocellular Carcinoma. Clinical Cancer Research, 2017, 23, 7333-7339.	7.0	128
65	Dual Inhibition of Hedgehog and c-Met Pathways for Pancreatic Cancer Treatment. Molecular Cancer Therapeutics, 2017, 16, 2399-2409.	4.1	27
66	Melanoma subtypes demonstrate distinct PD-L1 expression profiles. Laboratory Investigation, 2017, 97, 1063-1071.	3.7	156
67	Th17 immune microenvironment in Epstein-Barr virus–negative Hodgkin lymphoma: implications for immunotherapy. Blood Advances, 2017, 1, 1324-1334.	5.2	36
68	Somatically Acquired LINE-1 Insertions in Normal Esophagus Undergo Clonal Expansion in Esophageal Squamous Cell Carcinoma. Human Mutation, 2016, 37, 942-954.	2.5	43
69	Program Death 1 Immune Checkpoint and Tumor Microenvironment: Implications for Patients With Intrahepatic Cholangiocarcinoma. Annals of Surgical Oncology, 2016, 23, 2610-2617.	1.5	128
70	Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nature Reviews Cancer, 2016, 16, 275-287.	28.4	2,133
71	Cancer-Associated Fibroblasts in Pancreatic Cancer Are Reprogrammed by Tumor-Induced Alterations in Genomic DNA Methylation. Cancer Research, 2016, 76, 5395-5404.	0.9	95
72	The Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated with Anti–PD-1 Response in Patients with Renal Cell Carcinoma. Cancer Immunology Research, 2016, 4, 726-733.	3.4	133

#	Article	IF	CITATIONS
73	Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E7769-E7777.	7.1	145
74	Yes-associated protein impacts adherens junction assembly through regulating actin cytoskeleton organization. American Journal of Physiology - Renal Physiology, 2016, 311, G396-G411.	3.4	31
75	Fulminant Myocarditis with Combination Immune Checkpoint Blockade. New England Journal of Medicine, 2016, 375, 1749-1755.	27.0	1,668
76	Magnetoencapsulated human islets xenotransplanted into swine: a comparison of different transplantation sites. Xenotransplantation, 2016, 23, 211-221.	2.8	22
77	Ganetespib radiosensitization for liver cancer therapy. Cancer Biology and Therapy, 2016, 17, 457-466.	3.4	12
78	Using Quantitative Seroproteomics to Identify Antibody Biomarkers in Pancreatic Cancer. Cancer Immunology Research, 2016, 4, 225-233.	3.4	21
79	PD-L1 Expression as a Predictive Biomarker. JAMA Oncology, 2016, 2, 54.	7.1	43
80	Programmed death-1 blockade in mismatch repair deficient colorectal cancer Journal of Clinical Oncology, 2016, 34, 103-103.	1.6	50
81	PD-1 blockade in mismatch repair deficient non-colorectal gastrointestinal cancers Journal of Clinical Oncology, 2016, 34, 195-195.	1.6	39
82	Emerging role of Hpo signaling and YAP in hepatocellular carcinoma. Journal of Hepatocellular Carcinoma, 2015, 2, 69.	3.7	28
83	Rotavirus Infects Human Biliary Epithelial Cells and Stimulates Secretion of Cytokines IL-6 and IL-8 via MAPK Pathway. BioMed Research International, 2015, 2015, 1-9.	1.9	15
84	PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. New England Journal of Medicine, 2015, 372, 2509-2520.	27.0	7,696
85	Yes-associated protein in the liver: Regulation of hepatic development, repair, cell fate determination and tumorigenesis. Digestive and Liver Disease, 2015, 47, 826-835.	0.9	23
86	β-Catenin destruction complex-independent regulation of Hippo–YAP signaling by APC in intestinal tumorigenesis. Genes and Development, 2015, 29, 1493-1506.	5.9	155
87	Semaphorin 3D autocrine signaling mediates the metastatic role of annexin A2 in pancreatic cancer. Science Signaling, 2015, 8, ra77.	3.6	89
88	Homeostatic control of Hippo signaling activity revealed by an endogenous activating mutation in YAP. Genes and Development, 2015, 29, 1285-1297.	5.9	125
89	PD-1/PD-L1 Blockade Together With Vaccine Therapy Facilitates Effector T-Cell Infiltration Into Pancreatic Tumors. Journal of Immunotherapy, 2015, 38, 1-11.	2.4	333
90	PD-L1 Expression in Melanocytic Lesions Does Not Correlate with the BRAF V600E Mutation. Cancer Immunology Research, 2015, 3, 110-115.	3.4	45

#	Article	IF	CITATIONS
91	A polymeric nanoparticle formulation of curcumin in combination with sorafenib synergistically inhibits tumor growth and metastasis in an orthotopic model of human hepatocellular carcinoma. Biochemical and Biophysical Research Communications, 2015, 468, 525-532.	2.1	59
92	The prognostic value of stroma in pancreatic cancer in patients receiving adjuvant therapy. Hpb, 2015, 17, 292-298.	0.3	63
93	Widespread somatic L1 retrotransposition occurs early during gastrointestinal cancer evolution. Genome Research, 2015, 25, 1536-1545.	5.5	121
94	PARP14 promotes the Warburg effect in hepatocellular carcinoma by inhibiting JNK1-dependent PKM2 phosphorylation and activation. Nature Communications, 2015, 6, 7882.	12.8	177
95	LINE-1 expression and retrotransposition in Barrett's esophagus and esophageal carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E4894-900.	7.1	127
96	The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints. Cancer Discovery, 2015, 5, 43-51.	9.4	1,180
97	Adaptive immune resistance in gastro-esophageal cancer: Correlating tumoral/stromal PDL1 expression with CD8+ cell count Journal of Clinical Oncology, 2015, 33, 4031-4031.	1.6	1
98	PD-1 blockade in tumors with mismatch repair deficiency Journal of Clinical Oncology, 2015, 33, LBA100-LBA100.	1.6	22
99	PD-1 blockade in tumors with mismatch repair deficiency Journal of Clinical Oncology, 2015, 33, LBA100-LBA100.	1.6	31
100	Lymphocyte Activation Gene 3 (LAG-3) Modulates the Ability of CD4 T-cells to Be Suppressed In Vivo. PLoS ONE, 2014, 9, e109080.	2.5	138
101	Treatment and Prognosis of Patients with Fibrolamellar Hepatocellular Carcinoma: A National Perspective. Journal of the American College of Surgeons, 2014, 218, 196-205.	0.5	75
102	Immunotherapy Converts Nonimmunogenic Pancreatic Tumors into Immunogenic Foci of Immune Regulation. Cancer Immunology Research, 2014, 2, 616-631.	3.4	408
103	Genomic Profiling of Intrahepatic Cholangiocarcinoma: Refining Prognosis and Identifying Therapeutic Targets. Annals of Surgical Oncology, 2014, 21, 3827-3834.	1.5	123
104	Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy. Clinical Cancer Research, 2014, 20, 5064-5074.	7.0	2,050
105	Induction of Innate Lymphoid Cell-Derived Interleukin-22 by the Transcription Factor STAT3 Mediates Protection against Intestinal Infection. Immunity, 2014, 40, 25-39.	14.3	221
106	The use of Yes-associated protein expression in the diagnosis of persistent neonatal cholestatic liver disease. Human Pathology, 2014, 45, 1057-1064.	2.0	25
107	Peripheral and tumor immune correlates in patients with advanced melanoma treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) monotherapy or in combination with ipilimumab. Journal of Translational Medicine, 2014, 12, O8.	4.4	17
108	Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nature Genetics, 2013, 45, 1470-1473.	21.4	564

#	Article	IF	CITATIONS
109	Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody. Clinical Cancer Research, 2013, 19, 462-468.	7.0	485
110	The frequency of KRAS and BRAF mutations in intrahepatic cholangiocarcinomas and their correlation with clinical outcome. Human Pathology, 2013, 44, 2768-2773.	2.0	81
111	PD-L1 Expression in the Merkel Cell Carcinoma Microenvironment: Association with Inflammation, Merkel Cell Polyomavirus, and Overall Survival. Cancer Immunology Research, 2013, 1, 54-63.	3.4	333
112	Immunohistochemical Staining of B7-H1 (PD-L1) on Paraffin-embedded Slides of Pancreatic Adenocarcinoma Tissue. Journal of Visualized Experiments, 2013, , .	0.3	28
113	Abstract 446: Differential expression of immuno-regulatory genes associated with PD-L1 display: Implications for clinical blockade of the PD-1/PD-L1 pathway in melanoma , 2013, , .		1
114	Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape. Science Translational Medicine, 2012, 4, 127ra37.	12.4	1,837
115	Yesâ€associated protein regulates the hepatic response after bile duct ligation. Hepatology, 2012, 56, 1097-1107.	7.3	145
116	Expression of Yes-associated protein modulates Survivin expression in primary liver malignancies. Human Pathology, 2012, 43, 1376-1385.	2.0	41
117	Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer. New England Journal of Medicine, 2012, 366, 2443-2454.	27.0	10,727
118	Genetic and pharmacological disruption of the TEAD–YAP complex suppresses the oncogenic activity of YAP. Genes and Development, 2012, 26, 1300-1305.	5.9	1,135
119	Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. Nature Genetics, 2011, 43, 828-829.	21.4	392
120	Tyrosine 23 Phosphorylation-Dependent Cell-Surface Localization of Annexin A2 Is Required for Invasion and Metastases of Pancreatic Cancer. PLoS ONE, 2011, 6, e19390.	2.5	152
121	Yes-Associated Protein 1 Is Widely Expressed in Human Brain Tumors and Promotes Clioblastoma Growth. Journal of Neuropathology and Experimental Neurology, 2011, 70, 568-577.	1.7	138
122	Refining the definition of perioperative mortality following hepatectomy using death within 90 days as the standard criterion. Hpb, 2011, 13, 473-482.	0.3	140
123	A polymeric nanoparticle formulation of curcumin (NanoCurcâ,,¢) ameliorates CCl4-induced hepatic injury and fibrosis through reduction of pro-inflammatory cytokines and stellate cell activation. Laboratory Investigation, 2011, 91, 1383-1395.	3.7	98
124	The Merlin/NF2 Tumor Suppressor Functions through the YAP Oncoprotein to Regulate Tissue Homeostasis in Mammals. Developmental Cell, 2010, 19, 27-38.	7.0	663
125	Tc17 CD8 T Cells: Functional Plasticity and Subset Diversity. Journal of Immunology, 2009, 183, 7161-7168.	0.8	170
126	T Cell-Derived Lymphotoxin Regulates Liver Regeneration. Gastroenterology, 2009, 136, 694-704.e4.	1.3	66

8

#	Article	IF	CITATIONS
127	Expression of Yes-associated protein in common solid tumors. Human Pathology, 2008, 39, 1582-1589.	2.0	486
128	Gadd45β promotes hepatocyte survival during liver regeneration in mice by modulating JNK signaling. Journal of Clinical Investigation, 2008, 118, 1911-1923.	8.2	85
129	Elucidation of a Universal Size-Control Mechanism in Drosophila and Mammals. Cell, 2007, 130, 1120-1133.	28.9	2,026
130	Selective targeting of the LIGHT-HVEM costimulatory system for the treatment of graft-versus-host disease. Blood, 2007, 109, 4097-4104.	1.4	66
131	Biopsy Considerations in the Diagnosis of Hepatic Masses. Clinical Gastroenterology and Hepatology, 2007, 5, 541-544.	4.4	5
132	Fas-positive T cells regulate the resolution of airway inflammation in a murine model of asthma. Journal of Experimental Medicine, 2006, 203, 1173-1184.	8.5	66
133	Contribution of the Lymphotoxin β Receptor to Liver Regeneration. Journal of Immunology, 2005, 175, 1295-1300.	0.8	65
134	The Critical Role of LIGHT in Promoting Intestinal Inflammation and Crohn's Disease. Journal of Immunology, 2005, 174, 8173-8182.	0.8	82
135	The role of herpesvirus entry mediator as a negative regulator of T cell–mediated responses. Journal of Clinical Investigation, 2005, 115, 711-717.	8.2	169
136	Local expression of B7-H1 promotes organ-specific autoimmunity and transplant rejection. Journal of Clinical Investigation, 2004, 113, 694-700.	8.2	146
137	Dysregulated LIGHT expression on T cells mediates intestinal inflammation and contributes to IgA nephropathy. Journal of Clinical Investigation, 2004, 113, 826-835.	8.2	99